Product
OC-001
1 clinical trial
17 indications
Indication
CancerIndication
Metastatic CancerIndication
Triple-Negative Breast CancerIndication
Stomach CancerIndication
Cervical CancerIndication
Ovarian CancerIndication
Hepatocellular CarcinomaIndication
Squamous Cell Carcinoma of Head and NeckIndication
Bladder CancerIndication
Urothelial NeoplasmIndication
Lung CancerIndication
Renal Cell CarcinomaIndication
Locally Advanced Solid TumorIndication
Locally Advanced Malignant NeoplasmIndication
Squamous Cell CarcinomaIndication
SarcomaIndication
Merkel Cell CarcinomaClinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic CancersStatus: Recruiting, Estimated PCD: 2026-03-31